Clinical Impressions and Therapy Goals
Panelists discuss how managing extensive stage small cell lung cancer involves balancing the survival benefits of subsequent therapies with the risks of treatment-related adverse events, emphasizing the importance of individualized treatment strategies.
Video content above is prompted by the following:
Describe the case and your initial impressions:
- What would be the predominant goals of therapy for a patient such as this?
- In patients with extensive stage small cell lung cancer (ES-SCLC) that has progressed, how do you balance the survival benefits afforded by subsequent lines of therapy with risks of treatment-related adverse events after progression of disease on platinum-based primary therapy?
- For primary therapy of ES-SCLC, under what circumstances would you consider extending the cycles of chemoimmunotherapy from 4 to 6?
Related Content
